Author name: Immunwork Web Team

TE-8105 Featured in Tech Times, Highlighting Fatty Acid Bundle Engineering and Biweekly Dosing Potential

Reported /

International technology and health media Tech Times recently featured Immunwork’s long-acting GLP-1 receptor agonist TE-8105, highlighting its First-in-Human clinical results and novel fatty acid bundle molecular design. According to the report, TE-8105 is developed using Immunwork’s proprietary Fatty Acid Bundle Platform, which incorporates two long-chain fatty acids through a multi-arm linker to enhance albumin binding. […]

TE-8105 Featured in Tech Times, Highlighting Fatty Acid Bundle Engineering and Biweekly Dosing Potential Read More »

Immunwork’s Long-Acting GLP-1 Candidate TE-8105 Receives Dual International Recognition

Scientific Publication /

First-in-Human Clinical Results Published in The Journal of Clinical Pharmacology and Presented at WCP2026 T-E Pharma’s subsidiary, Immunwork, Inc., announced that the First-in-Human (FIH) Phase 1/2a clinical study results of TE-8105, a long-acting GLP-1 receptor agonist developed using Immunwork’s proprietary technology platform, have been published in the internationally recognized journal The Journal of Clinical Pharmacology. The publication, entitled

Immunwork’s Long-Acting GLP-1 Candidate TE-8105 Receives Dual International Recognition Read More »

Join our presentation at the BIO Asia-Taiwan 2026 Conference

Meeting /

We’re excited to announce that Dr. Art Hsing-Mao Chu, CEO of T-E PHARMA, will be presenting at the Investment Summit Session of BIO Asia–Taiwan 2026 conference. Time: 16:15-17:20 Roadshow, Wednesday, July 15, 2026 Venue: Room 701AB, 7F, TaiNEX2 Dr. Chu will present the latest R&D progress across our pipeline, including the most recent clinical progress

Join our presentation at the BIO Asia-Taiwan 2026 Conference Read More »

Our Core Technology Platform Published in the Journal of the Chinese Chemical Society

Scientific Publication /

T-E Pharma is honored to be invited by the Journal of the Chinese Chemical Society (JCCS) to publish a review article introducing our core technology platform “Multi-Arm Linkers”, highlighting its innovative design and broad applications in novel drug development. JCCS is one of Taiwan’s longest-established SCI-indexed chemistry journals. It is published by the Chemical Society

Our Core Technology Platform Published in the Journal of the Chinese Chemical Society Read More »

T-E Pharma Launches Pre-IPO Capital Raise Pursuing a Dual-Engine Strategy in Metabolic and Oncology Therapeutics; Targeting TPEx Emerging Stock Board Listing in Q4 2026

News /

T-E Pharma has officially launched its pre-initial public offering (pre-IPO) fundraising program. The proceeds will be used to accelerate the development of its novel therapeutic pipeline, expand its global strategic presence, and strengthen its capital structure. The company is also actively pursuing international partnership opportunities, with the goal of listing on the Taiwan Emerging Stock

T-E Pharma Launches Pre-IPO Capital Raise Pursuing a Dual-Engine Strategy in Metabolic and Oncology Therapeutics; Targeting TPEx Emerging Stock Board Listing in Q4 2026 Read More »

Our Latest Research Published in International Journal of Pharmaceutics

Scientific Publication /

Great news! The long-acting GLP-1 receptor agonist TE-8105 has achieved an innovative breakthrough in formulation development, successfully creating a more convenient sublingual delivery form! We are thrilled to announce the publication of our paper, entitled “Optimized sublingual delivery of dual fatty acid-conjugated GLP-1 receptor agonist TE-8105 produces durable efficacy in diabetic mice”, has been published

Our Latest Research Published in International Journal of Pharmaceutics Read More »

Join our presentation at the BIOLOGICS WORLD TAIWAN 2026

Meeting /

We are honored to announce that Dr. Tse-Wen Chang, Chairman of T-E Pharma, and Dr. Hsin-Mao Chu, CEO of the T-E Pharma, have been invited to participate in BIOLOGICS WORLD TAIWAN 2026, to be held in Taiwan, where they will deliver keynote presentations. BIOLOGICS WORLD TAIWAN is Taiwan’s premier annual biotherapeutics industry event, organized by the international

Join our presentation at the BIOLOGICS WORLD TAIWAN 2026 Read More »

T-E Pharma Hosts Annual Year-End Gala as Five Drug Candidates Reach Key Development Milestones

News /

T-E Pharma held its annual year-end gala on January 29, providing an overview of the Group’s R&D achievements and future strategic roadmap. Its subsidiaries, Immunwork and T-E Meds, currently have five drug candidates at critical stages of development. Among them, two candidates are expected to advance into Phase II or Phase IIb clinical trials, with

T-E Pharma Hosts Annual Year-End Gala as Five Drug Candidates Reach Key Development Milestones Read More »

An Interview with Chairman Tse-Wen Chang, Founder of Immunwork and T-E Meds: A Journey Through Science and Entrepreneurship

Reported /

Dr. Tse-Wen Chang, Chairman and Founder of Immunwork and T-E Meds, built his scientific career through National Tsing-Hua University, Harvard University, and the Massachusetts Institute of Technology (MIT), and went on to lead the development of Xolair, the world’s first anti-IgE drug—marking a groundbreaking milestone in the treatment of allergies and asthma. After achieving remarkable

An Interview with Chairman Tse-Wen Chang, Founder of Immunwork and T-E Meds: A Journey Through Science and Entrepreneurship Read More »

Scroll to Top